© Reuters. Real-world study supports value proposition of iRhythm's Zio
- Results from a real-world study, KP-RHYTHM, conducted by Kaiser Permanente showed the value of monitoring the burden of atrial fibrillation (AF) in predicting stroke risk in patients not on anticoagulant therapy. The data were just published in JAMA Cardiology.
- The study enrolled 1,965 patients who underwent 14 days of continuous ambulatory electrocardiogram (ECG) monitoring using iRhythm's ( -0.1%) Zio Service. It showed that AF burden lasting more than 11% of the total monitoring time was associated with a three-fold increase in stroke risk, independent of other known risk factors.
- EVP of Operations and Chief Clinical Officer Judy Lenane says, “We are proud that Zio by iRhythm’s extended continuous cardiac monitoring capability coupled with our algorithm’s ability to bridge AF episodes allowed the researchers to develop new insights, as it gave the researchers a more comprehensive picture of AF burden than has been available previously. This study adds to the growing body of research showing Zio by iRhythm has practical implications for clinical care. It is an important tool that helps physicians achieve certainty in a single test and accelerates care for their patients.”
- Now read: Audentes reports positive results from study of AT132 in XLMTM; shares up 7%